Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Date Founded



60 Jubilee Avenue,Milton Park,Abingdon, Oxfordshire OX14 4RX

Type of Company


Employees (Worldwide)




Company Description

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Adaptimmune Therapeutics PLC? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Executive Director

Chief Financial Officer & Principal Accounting Officer

Chief Operating Officer

Chief Medical Officer

Head, Autoimmune Group

Head of Process Development

Vice President & Head, BioMarker Research & Development

Director, Investor Relations

Senior Vice President, Clinical Development

Senior Vice President of Global Bio-Process & Development

Board of Directors

Venture Partner & Senior Advisor at NEA Management Co. LLC

Professional at Adaptimmune Therapeutics PLC

Professional at ObsEva SA

Chief Executive Officer & Executive Director at Adaptimmune Therapeutics PLC

General Partner at NEA Management Co. LLC

Professional at Arix Bioscience Plc

Chief Medical Officer at Moderna, Inc.

Professional at Adaptimmune Therapeutics PLC

Paths to Adaptimmune Therapeutics PLC
Potential Connections via
Relationship Science
Adaptimmune Therapeutics PLC
Owners & Shareholders
Details Hidden

Matrix Capital Management (MCM) seeks to generate an attractive risk-adjusted return by investing in a concentrated portfolio of long and short positions, following the classic hedge fund model through investments primarily in publicly traded equity securities, and in the case of the Restricted Fund, through both private and public investments. The firm invests primarily in equity securities, typically in the form of common stocks but investments may also include preferred stocks, convertible securities, warrants, stock purchase rights, depositary receipts, shares of investment companies and other equity-related interests. In addition, as market conditions or investment opportunities warrant, investments may include opportunistic investments in debt securities, without restriction as to any minimum rating criteria. MCM''s funds may purchase and write (sell) options on stocks, bonds, currencies or market indices, thus allowing the funds to leverage their returns from specific securities and engage in a wide range of transactions designed to enhance returns, such as securities lending and repurchase agreements. The firm may employ active portfolio management strategies both as a hedge against volatility and to produce additional income and capital appreciation. MCM employs a moderate degree of leverage.

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Details Hidden

Oracle Investment Management focuses on long/short investments in the US healthcare sector with an emphasis on pharmaceutical and biotechnology companies. The firm tends to invest in small-cap US companies but they also invest in mid-cap and large-cap companies and in Europe. The firm seeks to achieve strong absolute and risk-adjusted returns on both client and principals capital by anticipating key sub-sector themes and by identifying specific companies within those sub-sectors with unrecognized investment potential. They use fundamental research in their stock selection and maintain a medium turnover rate

Recent Transactions
Details Hidden

Adaptimmune Therapeutics PLC issued . USD American Depositary Shares

Details Hidden

Adaptimmune Therapeutics PLC issued American Depositary Shares

Transaction Advisors

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares


Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares


Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued American Depositary Shares


Advised onAdaptimmune Therapeutics PLC issued . USD American Depositary Shares


GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Key Stats and Financials As of 2018
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
Enterprise Value Sales
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Details Hidden

Foresite Capital invests in public and private healthcare companies. They are managing $2 billion assets.

Details Hidden

QVT Financial is a global multi-strategy hedge fund manager. The firm invests in structured finance, private placements, high yield and distressed debt to create its portfolios. The firm employs convertible arbitrage, investment grade, and capital structure arbitrage techniques along with closed-end fund arbitrage and various relative value-driven equity strategies such as risk arbitrage, fundamental relative value, statistical trades, and other special situations techniques to make investments.

Details Hidden

Oxford Spin-out Equity Management seeks investment opportunities in spin out companies of Isis Innovation Ltd. The fund target companies operating in the fields of diagnostics, med tech, pharma tools and services, other technologies, health technology, biosciences, medical, and drugs. It provides financing for early stage capital requirements.

Thermo Fisher Scientific, Inc. Computer Software | Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded in November 2006 and is headquartered in Waltham, MA.

University of Texas - MD Anderson Cancer Center Medical Support Services | Houston, TX

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Caladrius Biosciences, Inc. Biotechnology | Basking Ridge, New Jersey

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adaptimmune Therapeutics PLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adaptimmune Therapeutics PLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Adaptimmune Therapeutics PLC.
  • be_ixf; php_sdk; php_sdk_1.4.15